Evaluation of the Propensity of Patients Under rhGH to Envision a Modification of Their Treatment Regimen Toward LAGH

Launched by CLINIQUES UNIVERSITAIRES SAINT-LUC- UNIVERSITÉ CATHOLIQUE DE LOUVAIN · Aug 2, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how patients currently receiving daily injections of growth hormone (rhGH) feel about switching to a different treatment option called long-acting growth hormone (LAGH). LAGH can be injected less frequently—once a week, every two weeks, or even monthly—which may make it easier for patients to stick to their treatment. The trial aims to understand whether patients are open to this change, especially since LAGH has been shown to work just as well as daily injections in helping with growth and body composition.

To participate in this trial, patients must be between the ages of 0 and 18 and currently receiving rhGH treatment for conditions like growth hormone deficiency or Turner Syndrome. Importantly, there are no exclusions based on health condition. Participants will be asked to share their thoughts on switching to LAGH, and their input will help doctors determine the best treatment options for young patients in the future. This trial is currently recruiting participants in Belgium and Luxembourg, and it aims to ensure that any new treatments are safe and effective for those who need them.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Belgian and Luxembourgish patients currently under rhGh treatment in its various official indications (as per the Belgian RIZIV/INAMI monitor : growth hormone deficiency, Turner Syndrome, chronic renal insufficiency, Prader-Willi syndrome, Small for gestational age, Noonan Syndrome, SHOX gene deficiency) and included in the BELGROW Registry
• • Male -female
• • 0-18 years
• • Free written or e-consent and oral consent
• Exclusion Criteria:
• • No exclusion criteria